Glioma-derived plasminogen activator inhibitor-1 (PAI-1) regulates the recruitment of LRP1 positive mast cells

Glioblastoma (GBM) is a high-grade glioma with a complex microenvironment, including various inflammatory cells and mast cells (MCs) as one of them. Previously we had identified glioma grade-dependent MC recruitment. In the present study we investigated the role of plasminogen activator inhibitor 1 (PAI-1) in MC recruitment. PAI-1, a primary regulator in the fibrinolytic cascade is capable of forming a complex with fibrinolytic system proteins together with low-density lipoprotein receptor-related protein 1 (LRP1). We found that neutralizing PAI-1 attenuated infiltration of MCs. To address the potential implication of LRP1 in this process, we used a LRP1 antagonist, receptor-associated protein (RAP), and demonstrated the attenuation of MC migration. Moreover, a positive correlation between the number of MCs and the level of PAI-1 in a large cohort of human glioma samples was observed. Our study demonstrated the expression of LRP1 in human MC line LAD2 and in MCs in human high-grade glioma. The activation of potential PAI-1/LRP1 axis with purified PAI-1 promoted increased phosphorylation of STAT3 and subsequently exocytosis in MCs. These findings indicate the influence of the PAI-1/LRP1 axis on the recruitment of MCs in glioma. The connection between high-grade glioma and MC infiltration could contribute to patient tailored therapy and improve patient stratification in future therapeutic trials.

[1]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[2]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[3]  M Brada,et al.  High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  G. Reifenberger,et al.  EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.

[5]  G. Nilsson,et al.  Glioma‐derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5‐dependent manner , 2014, Molecular oncology.

[6]  F. Levi-Schaffer,et al.  Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis. , 2014, The Journal of allergy and clinical immunology.

[7]  Tao Jiang,et al.  Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. , 2013, Cancer letters.

[8]  P. May,et al.  The low-density lipoprotein receptor-related protein 1 in inflammation , 2013, Current opinion in lipidology.

[9]  A. Mazar,et al.  The Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye , 2013, Seminars in Thrombosis & Hemostasis.

[10]  C. Heldin,et al.  Snail depletes the tumorigenic potential of glioblastoma , 2013, Oncogene.

[11]  K. Suk,et al.  Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity , 2012, Journal of Neuroinflammation.

[12]  Caroline Kampf,et al.  Production of Tissue Microarrays, Immunohistochemistry Staining and Digitalization Within the Human Protein Atlas , 2012, Journal of visualized experiments : JoVE.

[13]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[14]  I. Alafuzoff,et al.  Mast Cell Accumulation in Glioblastoma with a Potential Role for Stem Cell Factor and Chemokine CXCL12 , 2011, PloS one.

[15]  Paul J. Higgins,et al.  PAI-1: An Integrator of Cell Signaling and Migration , 2011, International journal of cell biology.

[16]  B. Westermark,et al.  Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells , 2011, International journal of cancer.

[17]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[18]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[19]  O. Chinot,et al.  High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas , 2009, Acta Neuropathologica.

[20]  W. Weiss,et al.  Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines , 2009, Oncogene.

[21]  K. Khazaie,et al.  Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. , 2009, Biochimica et biophysica acta.

[22]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[23]  C. Gladson,et al.  New molecular targets in angiogenic vessels of glioblastoma tumours , 2008, Expert Reviews in Molecular Medicine.

[24]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[25]  J. McMurray A new small-molecule Stat3 inhibitor. , 2006, Chemistry & biology.

[26]  C. Heldin,et al.  Characterization of an imatinib-sensitive subset of high-grade human glioma cultures , 2006, Oncogene.

[27]  D. Metcalfe,et al.  Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. , 2003, Leukemia research.

[28]  A. Kaye,et al.  The role of the plasminogen activation cascade in glioma cell invasion: a review , 2003, Journal of Clinical Neuroscience.

[29]  Peter Hufnagl,et al.  Plasminogen activator inhibitor 1: physiological and pathophysiological roles. , 2002, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[30]  A. V. van Zonneveld,et al.  Molecular Analysis of Ligand Binding to the Second Cluster of Complement-type Repeats of the Low Density Lipoprotein Receptor-related Protein , 1997, The Journal of Biological Chemistry.

[31]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[32]  Michael Lim,et al.  Mechanisms of local immunoresistance in glioma. , 2010, Neurosurgery clinics of North America.

[33]  Y. Iwadate,et al.  High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. , 2008, Anticancer research.

[34]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[35]  T. Willnow,et al.  The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro. , 1996, The Biochemical journal.